CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery
PR Newswire —
This marks CytoReason's fifth commercial deal of 2025 and builds on its track record with half of the world's top twenty pharma companies, which have leveraged its technology across a range of programs. TEL AVIV, Israel, Jan. 9, 2026 /PRNewswire/ -- CytoReason, a leader in AI-powered...